Max Robotics — Global Service Robot Directory + US Certification

About

Sandeep Mittan is a rising investigator in urologic oncology whose work bridges inflammation and prostate cancer biology. His research centers on understanding how non-malignant pelvic conditions influence prostate cancer aggressiveness, a largely unexplored area with significant clinical implications. In his landmark 2022 study, Mittan was the first to systematically evaluate the association between incidental pelvic inflammation and aggressive prostate cancer phenotypes. By analyzing clinical outcomes in patients following radical prostatectomy, he demonstrated that pelvic inflammation may drive more aggressive disease, challenging conventional risk stratification models. Though early in his career, this work has already garnered 15 citations, signaling its growing influence among urologic oncologists and pathologists. Mittan’s findings open new avenues for incorporating inflammatory biomarkers into prostate cancer prognosis and treatment planning. His innovative approach—linking a common incidental finding to cancer biology—positions him as a promising voice in the effort to refine personalized risk assessment for prostate cancer patients.